Search

Your search keyword '"Fabi Alessandra"' showing total 1,013 results
Start Over Author "Fabi Alessandra"
1,013 results on '"Fabi Alessandra"'

1. Male breast cancer: a multicenter study to provide a guide for proper management

Author

Lissidini, Germana, Nicosia, Luca, Sargenti, Manuela, Cucchi, Maria Cristina, Fabi, Alessandra, Falco, Giuseppe, Gardani, Marco, Grilz, Greta, Maugeri, Ilaria, Murgo, Roberto, Neri, Alessandro, Pellini, Francesca, Sensi, Cristiana, Scomersi, Serena, Taffurelli, Mario, Bagnardi, Vincenzo, Oriecuia, Chiara, Pagan, Eleonora, Sangalli, Claudia, Dessena, Massimo, Veronesi, Paolo, and Galimberti, Viviana

Published
2024
Full Text
View/download PDF

2. Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer

Author

Cucciniello, Linda, Blondeaux, Eva, Bighin, Claudia, Gasparro, Simona, Russo, Stefania, Dri, Arianna, Pugliese, Palma, Fontana, Andrea, Cortesi, Enrico, Ferzi, Antonella, Riccardi, Ferdinando, Sini, Valentina, Boni, Luca, Fabi, Alessandra, Montemurro, Filippo, De Laurentiis, Michelino, Arpino, Grazia, Del Mastro, Lucia, Gerratana, Lorenzo, and Puglisi, Fabio

Published
2024
Full Text
View/download PDF

3. Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Author

Scagnoli, Simone, Pisegna, Simona, Toss, Angela, Caputo, Roberta, De Laurentiis, Michelino, Palleschi, Michela, de Giorgi, Ugo, Cortesi, Enrico, Fabbri, Agnese, Fabi, Alessandra, Paris, Ida, Orlandi, Armando, Curigliano, Giuseppe, Criscitiello, Carmen, Garrone, Ornella, Tomasello, Gianluca, D’Auria, Giuliana, Vici, Patrizia, Ricevuto, Enrico, Domati, Federica, Piombino, Claudia, Parola, Sara, Scafetta, Roberta, Cirillo, Alessio, Taurelli Salimbeni, Beatrice, Di Lisa, Francesca Sofia, Strigari, Lidia, Preissner, Robert, Simmaco, Maurizio, Santini, Daniele, Marchetti, Paolo, and Botticelli, Andrea

Published
2024
Full Text
View/download PDF

4. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Author

Scagnoli, Simone, Pisegna, Simona, Toss, Angela, Caputo, Roberta, De Laurentiis, Michelino, Palleschi, Michela, de Giorgi, Ugo, Cortesi, Enrico, Fabbri, Agnese, Fabi, Alessandra, Paris, Ida, Orlandi, Armando, Curigliano, Giuseppe, Criscitiello, Carmen, Garrone, Ornella, Tomasello, Gianluca, D’Auria, Giuliana, Vici, Patrizia, Ricevuto, Enrico, Domati, Federica, Piombino, Claudia, Parola, Sara, Scafetta, Roberta, Cirillo, Alessio, Taurelli Salimbeni, Beatrice, Di Lisa, Francesca Sofia, Strigari, Lidia, Preissner, Robert, Simmaco, Maurizio, Santini, Daniele, Marchetti, Paolo, and Botticelli, Andrea

Published
2024
Full Text
View/download PDF

5. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients

Author

Giordani, Elena, Allegretti, Matteo, Sinibaldi, Alberto, Michelotti, Francesco, Ferretti, Gianluigi, Ricciardi, Elena, Ziccheddu, Giovanna, Valenti, Fabio, Di Martino, Simona, Ercolani, Cristiana, Giannarelli, Diana, Arpino, Grazia, Gori, Stefania, Omarini, Claudia, Zambelli, Alberto, Bria, Emilio, Paris, Ida, Buglioni, Simonetta, Giacomini, Patrizio, and Fabi, Alessandra

Published
2024
Full Text
View/download PDF

6. TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

Author

Iachettini, Sara, Terrenato, Irene, Porru, Manuela, Di Vito, Serena, Rizzo, Angela, D’Angelo, Carmen, Petti, Eleonora, Dinami, Roberto, Maresca, Carmen, Di Benedetto, Anna, Palange, Aldo, Mulè, Antonino, Santoro, Angela, Palazzo, Antonella, Fuso, Paola, Stoppacciaro, Antonella, Vici, Patrizia, Filomeno, Lorena, Di Lisa, Francesca Sofia, Arcuri, Teresa, Krasniqi, Eriseld, Fabi, Alessandra, Biroccio, Annamaria, and Zizza, Pasquale

Published
2024
Full Text
View/download PDF

7. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Author

Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paola, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, and Scambia, Giovanni

Published
2024
Full Text
View/download PDF

10. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Author

Molinelli, Chiara, Bruzzone, Marco, Blondeaux, Eva, Ruelle, Tommaso, Lanzavecchia, Chiara, De Laurentiis, Michelino, Russo, Stefania, Riccardi, Ferdinando, Sini, Valentina, Cognetti, Francesco, Arpino, Grazia, Fabi, Alessandra, Pugliese, Palma, Collovà, Elena, Fontana, Andrea, Puglisi, Fabio, Bighin, Claudia, Lambertini, Matteo, and Del Mastro, Lucia

Published
2024
Full Text
View/download PDF

11. Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project

Author

Gori, Stefania, De Rose, Fiorenza, Ferro, Antonella, Fabi, Alessandra, Angiolini, Catia, Azzarello, Giuseppe, Cancian, Maurizio, Cinquini, Michela, Arecco, Luca, Aristei, Cynthia, Bernardi, Daniela, Biganzoli, Laura, Cariello, Anna, Cortesi, Laura, Cretella, Elisabetta, Criscitiello, Carmen, De Giorgi, Ugo, Carmen De Santis, Maria, Deledda, Giuseppe, Dessena, Massimo, Donati, Sara, Dri, Arianna, Ferretti, Gianluigi, Foglietta, Jennifer, Franceschini, Davide, Franco, Pierfrancesco, Schirone, Alessio, Generali, Daniele, Gianni, Lorenzo, Giordani, Stefano, Grandi, Giovanni, Cristina Leonardi, Maria, Magno, Stefano, Malorni, Luca, Mantoan, Carlotta, Martorana, Federica, Meattini, Icro, Meduri, Bruno, Merlini, Laura, Miglietta, Federica, Modena, Alessandra, Nicolis, Fabrizio, Palumbo, Isabella, Panizza, Pietro, Angela Rovera, Francesca, Salvini, Piermario, Santoro, Armando, Taffurelli, Mario, Toss, Angela, Tralongo, Paolo, Turazza, Monica, Valerio, Matteo, Verzè, Matteo, Vici, Patrizia, Zamagni, Claudio, Curigliano, Giuseppe, Pappagallo, Giovanni, and Zambelli, Alberto

Published
2024
Full Text
View/download PDF

12. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review

Author

Zambelli, Alberto, Cortesi, Laura, Gaudio, Mariangela, Arpino, Grazia, Bianchini, Giampaolo, Caruso, Francesco, Cinieri, Saverio, Curigliano, Giuseppe, Del Mastro, Lucia, De Placido, Sabino, Fabi, Alessandra, Fortunato, Lucio, Generali, Daniele, Gennari, Alessandra, Gori, Stefania, Grandi, Giovanni, Guarneri, Valentina, Klinger, Marco, Livi, Lorenzo, Marchiò, Caterina, Palumbo, Isabella, Panizza, Pietro, Pravettoni, Gabriella, Pruneri, Giancarlo, Puglisi, Fabio, Sapino, Anna, Tinterri, Corrado, Turchetti, Daniela, and De Laurentiis, Michelino

Published
2024
Full Text
View/download PDF

14. Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2

Author

Fabi, Alessandra, Cortesi, Laura, Duranti, Simona, Cordisco, Emanuela Lucci, Di Leone, Alba, Terribile, Daniela, Paris, Ida, de Belvis, Antonio Giulio, Orlandi, Armando, Marazzi, Fabio, Muratore, Margherita, Garganese, Giorgia, Fuso, Paola, Paoletti, Filippo, Dell’Aquila, Rossella, Minucci, Angelo, Scambia, Giovanni, Franceschini, Gianluca, Masetti, Riccardo, and Genuardi, Maurizio

Published
2024
Full Text
View/download PDF

17. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials

Author

Blondeaux, Eva, Xie, Wanling, Carmisciano, Luca, Mura, Silvia, Sanna, Valeria, De Laurentiis, Michelino, Caputo, Roberta, Turletti, Anna, Durando, Antonio, De Placido, Sabino, De Angelis, Carmine, Bisagni, Giancarlo, Gasparini, Elisa, Rimanti, Anita, Puglisi, Fabio, Mansutti, Mauro, Landucci, Elisabetta, Fabi, Alessandra, Arecco, Luca, Perachino, Marta, Bruzzone, Marco, Boni, Luca, Lambertini, Matteo, Del Mastro, Lucia, and Regan, Meredith M.

Published
2024
Full Text
View/download PDF

20. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Author

Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, Metro Giulio, Nisticò Cecilia, Papaldo Paola, De Vita Ferdinando, D’Auria Giuliana, Vidiri Antonello, Giannarelli Diana, and Cognetti Francesco

Subjects
Maintenance Bevacizumab, Antiangiogenic agents, HER2 negative metastatic breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT. Methods Thirty-five patients who experienced a response after first-line BT, were given mBev at the dose of 15 mg/kg every 3 weeks. Among 30 pts with hormonal receptor-positive metastatic breast cancer (MBC), 20 (66.6%) received HT with mBev (mHTBev). Objective of the study was the outcome and safety of mBev and in two groups of patients receiving HT or not. Results Complete response and partial response was achieved/maintained in 4 (11.4%) and 13 (37.1%) patients, respectively (overall response rate: 48.5%). Clinical benefit was obtained on 23 patients (65.7%). Median of mBev PFS and clinical benefit were 6.8 months (95% CI: 0.8-12.7) and 17.1 months (95% CI :12.2-21.9), respectively. Median PFS of patients who received mHTBev was longer than mBev without HT (13 months and 4.1 months, respectively, p = 0.05). The most common severe toxicities were proteinuria (11.4%) and hypertension (8.5%). No additional toxicity was observed with HTBev. Conclusion Maintenance bevacizumab with or without anti-hormonal therapy in patients with hormone receptor positive breast cancer is tolerable and associated with long-term clinical outcome; these results encourage the strategy of prolonging bevacizumab until progression in combination with anti-hormonal agents.

Published
2012
Full Text
View/download PDF

21. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation

Author

Vidiri Antonello, Pace Andrea, Fabi Alessandra, Maschio Marta, Latagliata Gaetano, Anelli Vincenzo, Piludu Francesca, Carapella Carmine, Giovinazzo Giuseppe, and Marzi Simona

Subjects
Perfusion CT, Anti-angiogenic therapy, Bevacizumab, Brain tumor, Hypoxia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background To determine whether early monitoring of the effects of bevacizumab in patients with recurrent high-grade gliomas, by a Perfusion Computed Tomography (PCT), may be a predictor of the response to treatment assessed through conventional MRI follow-up. Methods Sixteen patients were enrolled in the present study. For each patient, two PCT examinations, before and after the first dose of bevacizumab, were acquired. Areas of abnormal Cerebral Blood Volume (CBV) were manually defined on the CBV maps, using co-registered T1- weighted images, acquired before treatment, as a guide to the tumor location. Different perfusion metrics were derived from the histogram analysis of the normalized CBV (nCBV) maps; both hyper and hypo-perfused sub-volumes were quantified in the lesion, including tumor necrosis. A two-tailed Wilcoxon test was used to establish the significance of changes in the different perfusion metrics, observed at baseline and during treatment. The relationships between changes in perfusion and morphological MRI modifications at first follow-up were investigated. Results Significant reductions in mean and median nCBV were detected throughout the entire patient population, after only a single dose of bevacizumab. The nCBV histogram modifications indicated the normalization effect of bevacizumab on the tumor abnormal vasculature. An improvement in hypoxia after a single dose of bevacizumab was predictive of a greater reduction in T1-weighted contrast-enhanced volumes at first follow-up. Conclusions These preliminary results show that a quantification of changes in necrotic intra-tumoral regions could be proposed as a potential imaging biomarker of tumor response to anti-VEGF therapies.

Published
2012
Full Text
View/download PDF

22. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Author

Russillo Michelangelo, Nisticò Cecilia, Milella Michele, Carlini Paolo, Sperduti Isabella, Fabi Alessandra, Puglisi Fabio, Vaccaro Vanja, Bria Emilio, Cuppone Federica, Papaldo Paola, Ferretti Gianluigi, Aapro Matti, Giannarelli Diana, and Cognetti Francesco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile. Methods A literature-based meta-analysis to quantify the magnitude of benefit and safety of adding bevacizumab to chemotherapy for advanced breast cancer patients was conducted. Meta-regression and sensitivity analyses were also performed to identify additional predictors of outcome and to assess the influence of trial design. Results Five trials (3,841 patients) were gathered. A significant interaction according to treatment line was found for progression-free survival (PFS, p = 0.027); PFS was significantly improved for 1st line (Hazard Ratio, HR 0.68, p < 0.0001), with a 1-yr absolute difference (AD) of 8.4% (number needed to treat, NNT 12). A non-significant trend was found in overall survival (OS), and in PFS for 2nd line. Responses were improved with the addition of bevacizumab, without interaction between 1st line (Relative Risk, RR 1.46, p < 0.0001) and 2nd line (RR 1.58, p = 0.05). The most important toxicity was hypertension, accounting for a significant AD of 4.5% against bevacizumab (number needed to harm, NNH 22). Other significant, although less clinically meaningful, adverse events were proteinuria, neurotoxicity, febrile neutropenia, and bleeding. At the meta-regression analysis for 1st-line, more than 3 metastatic sites (p = 0.032), no adjuvant chemotherapy (p = 0.00013), negative hormonal receptor status (p = 0.009), and prior anthracyclines-exposure (p = 0.019), did significantly affect PFS. Conclusions Although with heterogeneity, the addition of bevacizumab to 1st-line chemotherapy significantly improves PFS, and overall activity. Hypertension should be weighted with the overall benefit on the individual basis.

Published
2011
Full Text
View/download PDF

23. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Author

Pace Andrea, Mansueto Giovanni, Lanzetta Gaetano, Russillo Michelangelo, Moscetti Luca, Telera Stefano, Bria Emilio, Mirri Alessandra, Metro Giulio, Felici Alessandra, Fabi Alessandra, Maschio Marta, Vidiri Antonello, Sperduti Isabella, Cognetti Francesco, and Carapella Carmine M

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background To evaluate the therapeutic strategies commonly employed in the clinic for the management of brain metastases (BMs) and to correlate disease outcome with type of treatment and therapeutic resources available at the treating center. Methods Four Cancer centres participated to the survey. Data were collected through a questionnaire filled in by one physician for each centre. Results Clinical data regarding 290 cancer patients with BMs from solid tumors were collected. Median age was 59 and 59% of patients had ≤ 3 brain metastases. A local approach (surgery and stereotactic radiosurgery) was adopted in 31% of patients. The local approach demonstrated to be superior in terms of survival compared to the regional/systemic approach (whole brain radiotherapy and chemotherapy, p = Conclusions In clinical practice, local strategies should be integrated in the management of brain metastases. Proper selection of patients who are candidate to local treatments is of crucial importance.

Published
2011
Full Text
View/download PDF

24. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine

Author

Carapella Maria Carmine, Pompili Alfredo, Fabi Alessandra, Pace Andrea, Vidiri Antonello, Dinapoli Loredana, Maschio Marta, and Jandolo Bruno

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Seizure control doesn't represent the only challenging goal in patients with brain tumor-related epilepsy. Side effects have often taken precedence for patients' quality of life. Methods We performed an observational retrospective study on patients with brain tumor-related epilepsy: 35 who had assumed oxcarbazepine monotherapy and 35 patients who had undergone treatment with traditional antiepileptic drugs. Primary variable of efficacy was the mean seizure frequency per month and safety variables were the drop-out for side effects and total incidence of side effects. We applied the Propensity Score technique to minimize selection bias. Results Our results showed a similar efficacy of oxcarbazepine and traditional antiepileptic drugs over time, but the difference in safety and tolerability between the two groups was significant: traditional AEDs caused more side effects, both serious and non serious. Conclusion This study highlights the importance of taking into consideration not only seizure control but also the appearance of side effects when choosing antiepileptic drugs in this patients population.

Published
2009
Full Text
View/download PDF

25. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

Author

Mirri Maria, Jandolo Bruno, Cognetti Francesco, Maschio Marta, Carapella Carmine, Vidiri Antonello, Russillo Michelangelo, Metro Giulio, Fabi Alessandra, Sperduti Isabella, Telera Stefano, Carosi Mariantonia, and Pace Andrea

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background In recurrent malignant gliomas (MGs), a high rate of haematological toxicity is observed with the use of fotemustine at the conventional schedule (100 mg/m2 weekly for 3 consecutive weeks followed by triweekly administration after a 5-week rest period). Also, the impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status on fotemustine activity has never been explored in the clinical setting. Methods 40 patients with recurrent pretreated MG were identified as being treated with fotemustine at doses ranging from 65 mg/m2 to 100 mg/m2. Patients were classified into 3 groups according to the dose of fotemustine received, from the lowest dosage received in group A, to the highest in group C. Analysis of MGMT promoter methylation in tumor tissue was successfully performed in 19 patients. Results Overall, 20% of patients responded to treatment, for a disease control rate (DCR, responses plus stabilizations) of 47.5%. Groups A and B experienced a response rate of 40% and 26.5% respectively, while the corresponding value for group C was 10%. Out of 19 patients, MGMT promoter was found methylated in 12 cases among which a DCR of 66.5% was observed. All 7 patients with unmethylated MGMT promoter were progressive to fotemustine. Conclusion Low-dose fotemustine at 65–75 mg/m2 (induction phase) followed by 75–85 mg/m2 (maintenance phase) has an activity comparable to that of the conventional schedule. By determination of the MGMT promoter methylation status patients might be identified who are more likely to benefit from fotemustine chemotherapy.

Published
2009
Full Text
View/download PDF

26. Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases

Author

Di Nallo Anna, Vidiri Antonello, Marzi Simona, Mirri Alessandra, Fabi Alessandra, Carapella Carmine, Pace Andrea, and Crecco Marcello

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The paper reports a quantitative analysis of the perfusion maps of 22 patients, affected by gliomas or by metastasis, with the aim of characterizing the malignant tissue with respect to the normal tissue. The gold standard was obtained by histological exam or nuclear medicine techniques. The perfusion scan provided 11 parametric maps, including Cerebral Blood Volume (CBV), Cerebral Blood Flow (CBF), Average Perfusion (Pmean) and Permeability-surface area product (PS). Methods The perfusion scans were performed after the injection of 40 ml of non-ionic contrast agent, at an injection rate of 8 ml/s, and a 40 s cine scan with 1 s interval was acquired. An expert radiologist outlined the region of interest (ROI) on the unenhanced CT scan, by using a home-made routine. The mean values with their standard deviations inside the outlined ROIs and the contralateral ROIs were calculated on each map. Statistical analyses were used to investigate significant differences between diseased and normal regions. Receiving Operating Characteristic (ROC) curves were also generated. Results Tumors are characterized by higher values of all the perfusion parameters, but after the statistical analysis, only the PS, PatRsq (Patlak Rsquare) and Tpeak (Time to Peak) resulted significant. ROC curves, confirmed both PatRsq and PS as equally reliable metrics for discriminating between malignant and normal tissues, with areas under curves (AUCs) of 0.82 and 0.81, respectively. Conclusion CT perfusion is a useful and non invasive technique for evaluating brain neoplasms. Malignant and normal tissues can be accurately differentiated using perfusion map, with the aim of performing tumor diagnosis and grading, and follow-up analysis.

Published
2009
Full Text
View/download PDF

29. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Author

Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paola, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, and Scambia, Giovanni

Published
2023
Full Text
View/download PDF

30. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Author

Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paolo, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, and Scambia, Giovanni

Published
2023
Full Text
View/download PDF

31. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

Author

Giacomini, Patrizio, Valenti, Fabio, Allegretti, Matteo, Pallocca, Matteo, De Nicola, Francesca, Ciuffreda, Ludovica, Fanciulli, Maurizio, Scalera, Stefano, Buglioni, Simonetta, Melucci, Elisa, Casini, Beatrice, Carosi, Mariantonia, Pescarmona, Edoardo, Giordani, Elena, Sperati, Francesca, Jannitti, Nicoletta, Betti, Martina, Maugeri-Saccà, Marcello, Cecere, Fabiana Letizia, Villani, Veronica, Pace, Andrea, Appetecchia, Marialuisa, Vici, Patrizia, Savarese, Antonella, Krasniqi, Eriseld, Ferraresi, Virginia, Russillo, Michelangelo, Fabi, Alessandra, Landi, Lorenza, Minuti, Gabriele, Cappuzzo, Federico, Zeuli, Massimo, and Ciliberto, Gennaro

Published
2023
Full Text
View/download PDF

32. Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study

Author

Rossi, Alessandro, Aimar, Giacomo, Audisio, Marco, Bungaro, Maristella, Caglio, Andrea, Di Liello, Raimondo, Gamba, Teresa, Gargiulo, Piera, Ghisoni, Eleonora, Lombardi, Pasquale, Marandino, Laura, Mariniello, Annapaola, Paratore, Chiara, Reale, Maria Lucia, Trastu, Federica, Tuninetti, Valentina, Turco, Fabio, Fabi, Alessandra, Perrone, Francesco, and Di Maio, Massimo

Published
2023
Full Text
View/download PDF

33. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, Matteo, Blondeaux, Eva, Bisagni, Giancarlo, Mura, Silvia, De Placido, Sabino, De Laurentiis, Michelino, Fabi, Alessandra, Rimanti, Anita, Michelotti, Andrea, Mansutti, Mauro, Russo, Antonio, Montemurro, Filippo, Frassoldati, Antonio, Durando, Antonio, Gori, Stefania, Turletti, Anna, Tamberi, Stefano, Urracci, Ylenia, Fregatti, Piero, Razeti, Maria Grazia, Caputo, Roberta, De Angelis, Carmine, Sanna, Valeria, Gasparini, Elisa, Agostinetto, Elisa, de Azambuja, Evandro, Poggio, Francesca, Boni, Luca, and Del Mastro, Lucia

Published
2023
Full Text
View/download PDF

35. Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study

Author

De Laurentiis, Michelino, Caputo, Roberta, Mazza, Manuelita, Mansutti, Mauro, Masetti, Riccardo, Ballatore, Zelmira, Torrisi, Rosalba, Michelotti, Andrea, Zambelli, Alberto, Ferro, Antonella, Generali, Daniele, Vici, Patrizia, Coltelli, Luigi, Fabi, Alessandra, Marchetti, Paolo, Ballestrero, Alberto, Spazzapan, Simon, Frassoldati, Antonio, Sarobba, Maria Giuseppina, Grasso, Donatella, and Zamagni, Claudio

Published
2022
Full Text
View/download PDF

37. Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.

Author

Mastrantoni, Luca, Garufi, Giovanna, Giordano, Giulia, Maliziola, Noemi, Di Monte, Elena, Arcuri, Giorgia, Frescura, Valentina, Rotondi, Angelachiara, Orlandi, Armando, Carbognin, Luisa, Palazzo, Antonella, Miglietta, Federica, Pontolillo, Letizia, Fabi, Alessandra, Gerratana, Lorenzo, Pannunzio, Sergio, Paris, Ida, Pilotto, Sara, Marazzi, Fabio, and Franco, Antonio

Published
2025
Full Text
View/download PDF

38. Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.

Author

Fabi, Alessandra, Rossi, Alessandro, Caputo, Roberta, Pisegna, Simona, Scagnoli, Simone, Pantano, Francesco, D'Auria, Giuliana, Fedele, Palma, Fabbri, Agnese, Vernieri, Claudio, Palleschi, Michela, Carbognin, Luisa, Ferretti, Gianluigi, Di Monte, Elena, Paris, Ida, Pavese, Francesco, Garrone, Ornella, Franco, Antonio, De Laurentiis, Michelino, and Franceschini, Gianluca

Subjects
HER2 positive breast cancer, CENTRAL nervous system tumors, PROGRESSION-free survival, MEDICAL sciences, OVERALL survival
Abstract

Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, a real-world evidence is lacking in literature. We conducted a multicenter, observational, retrospective real-world analysis on 39 cases collected at 12 Italian Oncological Units. Patients with brain metastases (BMs) from HER2 + BC treated with T-DXd in various treatment lines were enrolled. Primary endpoint was the intracranial overall response rate (iORR). Secondary endpoints were intra- and global progression free survival (iPFS - gPFS); other secondary objectives were the intracranial disease control rate (iDCR), duration of response (iDoR), clinical benefit rate at 6 and 12 months (iCBr), overall survival, and safety. iORR was 59%, iPFS was 15.6 months, gPFS was 11.8 months. iDCR was 94.9%, iDoR was 11.9 months, and iCBr at 6 and 12 months were 69.2% and 59%, respectively. OS was not reached, with an overall rate of 77.9% of patients alive at 12 months. This study confirmed the high intracranial efficacy and manageable safety profile of T-DXd in this first-ever real world analysis. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

39. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Author

Del Mastro, Lucia, Mansutti, Mauro, Bisagni, Giancarlo, Ponzone, Riccardo, Durando, Antonio, Amaducci, Laura, Campadelli, Enrico, Cognetti, Francesco, Frassoldati, Antonio, Michelotti, Andrea, Mura, Silvia, Urracci, Ylenia, Sanna, Giovanni, Gori, Stefania, De Placido, Sabino, Garrone, Ornella, Fabi, Alessandra, Barone, Carla, Tamberi, Stefano, Bighin, Claudia, Puglisi, Fabio, Moretti, Gabriella, Arpino, Grazia, Ballestrero, Alberto, Poggio, Francesca, Lambertini, Matteo, Montemurro, Filippo, and Bruzzi, Paolo

Published
2021
Full Text
View/download PDF

40. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

Author

La Verde, Nicla, Damia, Giovanna, Garrone, Ornella, Santini, Daniele, Fabi, Alessandra, Ciccarese, Mariangela, Generali, Daniele Giulio, Nunzi, Martina, Poletto, Elena, Ferraris, Elisa, Cretella, Elisabetta, Scandurra, Giuseppa, Meattini, Icro, Bertolini, Alessandro Stefano, Cavanna, Luigi, Collovà, Elena, Romagnoli, Emanuela, Rulli, Eliana, Legramandi, Lorenzo, Guffanti, Federica, Bramati, Annalisa, Moretti, Anna, Cassano, Alessandra, Vici, Patrizia, Torri, Valter, and Farina, Gabriella

Published
2022
Full Text
View/download PDF

42. Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response. Development of GRADE (Grades of recommendation, assessment, Development and Evaluation) recommendation by the Italian Association of radiation therapy and Clinical Oncology (AIRO)

Author

Marino, Lorenza, Lancellotta, Valentina, Franco, Pierfrancesco, Meattini, Icro, Meduri, Bruno, Bernini, Marco, Fabi, Alessandra, Corvò, Renzo, Magrini, Stefano M., Pappagallo, Giovanni L., Arcangeli, Stefano, and D’Angelillo, Rolando M.

Published
2021
Full Text
View/download PDF

44. p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study

Author

Fabi, Alessandra, Mottolese, Marcella, Di Benedetto, Anna, Sperati, Francesca, Ercolani, Cristiana, Buglioni, Simonetta, Nisticò, Cecilia, Ferretti, Gianluigi, Vici, Patrizia, Perracchio, Letizia, Malaguti, Paola, Russillo, Michelangelo, Botti, Claudio, Pescarmona, Edoardo, Cognetti, Francesco, and Terrenato, Irene

Published
2020
Full Text
View/download PDF

46. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Author

Conte, Benedetta, Fabi, Alessandra, Poggio, Francesca, Blondeaux, Eva, Dellepiane, Chiara, D’Alonzo, Alessia, Buono, Giuseppe, Arpino, Grazia, Magri, Valentina, Naso, Giuseppe, Presti, Daniele, Mura, Silvia, Fontana, Andrea, Cognetti, Francesco, Molinelli, Chiara, Pastorino, Simona, Bighin, Claudia, Miglietta, Loredana, Boccardo, Francesco, Lambertini, Matteo, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

47. Trastuzumab Deruxtecan in brain metastases from breast cancer: outcome analysis of real life population

Author

Rossi, Alessandro, primary, Fabi, Alessandra, additional, Caputo, Roberta, additional, Pisegna, Simona, additional, Scagnoli, Simone, additional, Pantano, Francesco, additional, D'Auria, Giuliana, additional, Fedele, Palma, additional, Fabbri, Agnese, additional, Vernieri, Claudio, additional, Palleschi, Michela, additional, Carbognin, Luisa, additional, Ferretti, Gianliugi, additional, Monte, Elena Di, additional, Paris, Ida, additional, Pavese, Francesco, additional, Garrone, Ornella, additional, Franco, Antonio, additional, De Laurentiis, Michelino, additional, Franceschini, Gianluca, additional, Scambia, Giovanni, additional, Giannarelli, Diana, additional, Masetti, Riccardo, additional, and Botticelli, Andrea, additional

Published
2024
Full Text
View/download PDF

48. Simultaneous Integrated Boost (Sib) Intensity-Modulated Radiotherapy for Treatment of Bone Metastases: Analysis of a Breast Cancer Cohort

Author

Marazzi, Fabio, primary, Masiello, Valeria, additional, Fabi, Alessandra, additional, Manfrida, Stefania, additional, Corvari, Barbara, additional, Lancellotta, Valentina, additional, Mazzarella, Ciro, additional, Longo, Silvia, additional, De Angeli, Martina, additional, Moschella, Francesca, additional, Di Leone, Alba, additional, Orlandi, Armando, additional, Bracci, Serena, additional, Colloca, Giuseppe Ferdinando, additional, Massaccesi, Mariangela, additional, Boldrini, Luca, additional, Tagliaferri, Luca, additional, Franceschini, Gianluca, additional, Bria, Emilio, additional, Masetti, Riccardo, additional, Valentini, Vincenzo, additional, Gambacorta, Maria Antonietta, additional, and CELLINI, Francesco, additional

Published
2024
Full Text
View/download PDF

49. Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.

Author

Botticelli, Andrea, primary, Fabi, Alessandra, additional, Rossi, Alessandro, additional, Caputo, Roberta, additional, Pisegna, Simona, additional, Pantano, Francesco, additional, D'Auria, Giuliana, additional, Carbognin, Luisa, additional, Fedele, Palma, additional, Fabbri, Agnese, additional, Vernieri, Claudio, additional, Palleschi, Michela, additional, Ferretti, Gianluigi, additional, Paris, Ida, additional, Di Monte, Elena, additional, Pavese, Francesco, additional, Garrone, Ornella, additional, Giannarelli, Diana, additional, De Laurentiis, Michelino, additional, and Scambia, Giovanni, additional

Published
2024
Full Text
View/download PDF

50. Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial.

Author

Molinelli, Chiara, primary, Delucchi, Virginia, additional, Blondeaux, Eva, additional, Boni, Luca, additional, Poggio, Francesca, additional, Arpino, Grazia, additional, Nisticò, Cecilia, additional, Fabi, Alessandra, additional, De Laurentiis, Michelino, additional, Puglisi, Fabio, additional, Nader Marta, Guilherme, additional, Fozza, Alessandra, additional, Pitto, Francesca, additional, Lambertini, Matteo, additional, and Del Mastro, Lucia, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results